DigitalOcean Holdings Inc vs Summit Therapeutics Inc — how do they compare? DigitalOcean Holdings Inc trades at $134.84 (market cap $14.21B), while Summit Therapeutics Inc trades at $15.25 (market cap $12.06B). The key difference: DigitalOcean Holdings Inc is the larger of the two by market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| DOCN | SMMT | |
|---|---|---|
Market Cap | $14.21B | $12.06B |
Sector | Technology | Health |
52-Week High | $181.29 | $26.98 |
52-Week Low | $29.99 | $12.55 |
Enterprise Value | $14.97B | $11.39B |
Signals from Pluang's Aura AI — not financial advice
DigitalOcean (DOCN) trades at $129.73, up 4.49% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical outlook with support at $124 and resistance at $135. Revenue growth accelerated to 29% year-over-year in Q2 2026, driven by surging AI-native cloud demand, while maintaining robust 40% adjusted EBITDA margins. Analyst consensus remains strongly positive with a $173.71 price target representing 34% upside potential.
DOCN presents compelling growth exposure to the AI infrastructure boom with accelerating revenue and strong profitability, though elevated valuation multiples (P/E 54.94) and high leverage ($1.49B debt) warrant caution. The company's strategic positioning in AI inference workloads and raised 2026 guidance support continued upside, but investors should monitor competitive pressures and execution risks in the rapidly evolving cloud market.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Trailing returns across standard periods
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →